Sternsdorf T , Jensen K , Will H .

	Figure 2. Immunoblot analysis of in vitro translated PML, SpAlt-C, and the Sp100 protein as well as of proteins of total cell extracts from various cells (HuH-7 cells transfected with PML, SpAlt-C and Sp100 expression vectors, induced HeLa-PML++ and HeLa-SpAltC++ cells, and HeLa S3 cells with and without prior treatment with IFN) separated by 7.5% SDS-PAGE. PML protein synthesized in vitro (lane 1, IVTL PML) has a higher electrophoretic mobility (band A) than the same PML protein expressed in transiently transfected HuH-7 (lane 2, band B) or in HeLa-PML++ cells (lane 3, band B), the latter showing additional bands of lower electrophoretic mobility (lane 3, bands C–F). PML proteins expressed from the endogenous gene are visualized as multiple bands in IFN-treated HeLa S3 cells (lane 5). In untreated cells, only the most prominent one is observed (lane 4). SpAlt-C protein comigrates when synthesized in vitro or in HuH-7 cells (lanes 6 and 7, band I). When expressed in HeLa-SpAltC++ cells (lane 8, band I), an additional band corresponding to a 110-kD protein is visualized (lane 8, band II). The Sp100 protein translated in vitro differs from that expressed transiently in HuH-7 cells by ∼3 kD (lane 10, bands III and IV). Sp100 proteins expressed from the endogenous gene in IFN-treated HeLa S3 cells are visualized as multiple bands; the major ones are indicated (lane 12, bands IV–VI). In untreated HeLa S3 cells, little Sp100 protein is detected (lane 11).
	Figure 3. Immunoblot with proteins of total extracts from noninduced (lanes + TET) and induced (lanes Ø TET) HeLa-PML++ and HeLa-SpAltC++ cells, and of untreated (lanes Ø) and IFN-treated (lanes IFN) HeLa S3 cells, separated by 12.5% SDS-PAGE. For detection, blots were incubated with polyclonal rat-anti-PML (PML), rat-anti-Sp100 (Sp100) Abs, and PIC1/SUMO-1–specific mAb 21C7 (21C7). In induced HeLa-PML++ cells, several strong bands were stained with anti-PML Abs (bands B–F) but only some of them (bands C–F) with anti-PIC1/SUMO-1 mAb. This indicates covalent linkage of PIC1/ SUMO-1 or a related polypeptide to proteins in the latter bands. In induced HeLa-SpAltC++, two major bands emerged when stained with anti-Sp100 Abs (bands I and II), whereas only the protein in band II, but not in band I, reacted with mAb 21C7. This indicates that band II represents the PIC1/SUMO-1–like modified form of the protein present in band I. In total extracts from untreated and IFN-treated HeLa S3 cells, a minor increase in staining by mAb 21C7 after IFN treatment in the range of 100–200 kD was observed. In all lanes, a 90-kD protein was recognized (band RG), which represents PIC1/SUMO-1–modified RanGAP1 protein (compare Fig. 4). Staining of the same blots with Ponceau S shows similar amounts of protein in all lanes (right; Ponceau S, shown for HeLa-SpAltC++).
	Figure 4. Detection of endogenous Sp100 carrying the PIC1/ SUMO1–like modification after immunoprecipitation from total nuclear extracts of HuH-7 cells with rabbit anti-Sp100 Abs (SpDF). Immunoblot of total nuclear extracts (lanes NE total), supernatants (lanes SN), and precipitates (lanes IP) from untreated (lanes Ø) and IFN-treated (lanes IFN) cells, separated on a 7.5% SDS gel. Blots were incubated with rat anti-Sp100 Abs, mAb 19C7 (specific for RanGAP1), 21C7 (specific for PIC1/ SUMO-1), or Ubi-1 (specific for ubiquitin). After immunoprecipitation, Sp100 proteins are detected in the precipitate of IFN-treated cells but hardly in the precipitate of untreated cells or in the supernatant. When incubated with mAb 21C7, a band corresponding to Sp100 band V became visible only in the precipitate of IFN-treated cells but not of untreated cells, indicating that band V corresponds to a PIC1/SUMO-1–modified form of Sp100. A large number of bands became visible in the supernatant, with the most prominent band at a relative mobility of 90 kD. Control staining of a parallel blot with mAb 19C7 confirms that this band represents the PIC1/SUMO-1–modified form of the RanGAP protein (shown for supernatant of IFN-treated cells; position of RanGAP marked by asterisk). A blot with the same extracts stained with a ubiquitin-specific mAb showed no detectable reactive protein in the precipitate, even after long exposure of the blot. In contrast, many bands corresponding to ubiquitinylated cellular proteins were observed in the supernatant.
	Figure 5. Immunofluorescence staining of induced and noninduced HeLa-SpAltC++ and HeLa-PML++ cells fixed with methanol/acetone. In induced HeLa-PML++ cells, rat anti-PML Ab shows bright and enlarged ND staining in nonmitotic cells and large aggregates in a mitotic cell (A, arrow), whereas only a few small dots were stained in the noninduced cells (D). Double staining of the same slides with mAb 21C7 shows overlapping ND staining in induced nonmitotic cells (D) and a diffuse homogeneous pattern in noninduced cells (E). In mitosis, induced HeLa-PML++ cells resulted in no staining of PML aggregates with mAb 21C7 (B, arrow). For comparison, phase contrast images are given in C and F. In induced HeLa-SpAltC++ cells, rabbit anti-Sp100 Abs resulted in a microspeckled pattern with some large dots (G), whereas only a few small dots were stained in the noninduced cells (K). Additional incubation of the same slides with mAb 21C7 led to homogenous staining both in induced (H) and noninduced cells (L). For comparison, phase contrast images are given in I and M. Bar, 10 μm.
	Figure 6. Immunofluorescence staining of methanol/ acetone-fixed, IFN-treated HeLa S3 cells. Cells were either double-labeled with polyclonal rat anti-PML (green) and mAb 21C7 (red) (A–C), with polyclonal rabbit anti-Sp100 antibodies (green) and mAb 21C7 (red) (D to F), or with anti-PML Abs and anti-Sp100 Abs (G–I). In a mitotic cell, PML is aggregated at the periphery of the cell (A and G, arrow), whereas Sp100 and PIC1/ SUMO-1 are diffusely distributed (B, D, E, and H), indicating that PIC1/SUMO-1 and Sp100 dissociate from PML in mitosis. Bar, 10 μm.
	Figure 7. (A) Differentiation of nuclear and cytoplasmic forms of Sp100 proteins from various untreated (Ø) and IFN-treated (IFN) cell lines on immunoblots (12.5% SDS-PAGE) incubated with anti-Sp100 antibodies. With the exception of HuH-7, an Sp100 protein of ∼88 kD (band IV) is detected not only in the nuclear (lanes N) but also in the cytoplasmic fractions (lanes C) of all cell lines tested. In untreated HuH-7 cells, this protein is detected exclusively in the cytoplasmic fraction. With the exception of MG63 cells, IFN treatment strongly increases Sp100 levels in the nuclear fractions and only moderately in the cytoplasmic fractions. Isoforms of Sp100 with slower electrophoretic mobility (bands V–VII, arrow) are detectable only in the nuclear fractions. A similar amount of proteins of the respective fractions was loaded as documented by Ponceau S staining (Ponceau). (B) Immunoblot with nuclear and cytoplasmic extracts of HuH-7 and HEp-2 cells and polyclonal rabbit anti-HNF-1 (HNF-1) and monoclonal anti-Sp1 (Sp1) antibodies, and a human autoimmune serum, recognizing among other proteins the mitochondrial 74-kD dihydrolipoamide acetyltransferase subunit (p74). The transcription factors HNF-1 and Sp1 are detected predominantly in the nuclear fraction (lanes N) of HuH-7 or HuH-7 and HEp-2, cells, respectively (arrows). In contrast, the 74-kD mitochondrial protein was detected exclusively in the cytoplasmic fraction of HEp-2 cells (p74, lanes C, arrow). Treatment of the cells with interferon does not alter the subcellular localization of these proteins (lanes IFN). Lanes LM, Ponceau S staining of the molecular mass marker of the corresponding blots. (C) Differentiation of nuclear and cytoplasmic forms of Sp100 proteins in untreated (Ø) and IFN-treated (IFN) HeLa S3 cells, in induced (ØTet) and noninduced (+Tet) HeLa-PML++ as well as in HeLa-SpAlt-C++ cells by immunoblotting (12.5% SDS-PAGE) with anti-Sp100 or anti-PML antibodies. Similar to A, Sp100 as well as PML proteins are both in the nuclear (lanes N) and cytoplasmic (lanes C) fractions. IFN treatment as well as induction of HeLa-PML++ or HeLa-SpAltC++ cells increase their amounts predominantly in the nuclear fraction. Modified Sp100 proteins (bands II, V, and VI) are exclusively nuclear. Modified PML protein also is detected exclusively in nuclei of HeLa-PML++ cells. This is not evident in nontransfected HeLa S3 cells. Little Sp100 and PML proteins are detected in a nuclear wash fraction (lanes W).
	Figure 8. Detection of cytoplasmic Sp100 protein in a coculture of human HuH-7 and rat R1H cells by immunofluorescence analysis. Untreated HuH-7 cells when stained with polyclonal rabbit anti-Sp100 Abs (Sp26) lack ND staining but show cytoplasmic fluorescence (Sp100/Ø). After treatment with IFN, a clear ND staining became visible in addition to the cytoplasmic staining (Sp100/IFN). Both images were taken at the same exposure time. At this exposure, rat R1H cells are not visibly stained by the Abs and serve as an internal negative control. Localization of the rat cells is visible in the corresponding phase contrast pictures given below. Bar, 10 μm.

Ahn, Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML. 1995, Pubmed

Ahn, Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML. 1995, Pubmed
Altabef, A retrovirus carrying the promyelocyte-retinoic acid receptor PML-RARalpha fusion gene transforms haematopoietic progenitors in vitro and induces acute leukaemias. 1996, Pubmed
Arnason, Stress resistance in Saccharomyces cerevisiae is strongly correlated with assembly of a novel type of multiubiquitin chain. 1994, Pubmed
Ascoli, Identification of a novel nuclear domain. 1991, Pubmed
Aso, Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. 1995, Pubmed
Baboshina, Novel multiubiquitin chain linkages catalyzed by the conjugating enzymes E2EPF and RAD6 are recognized by 26 S proteasome subunit 5. 1996, Pubmed
Bernstein, Diversity of autoantibodies in primary biliary cirrhosis and chronic active hepatitis. 1984, Pubmed
Biggins, Yeast ubiquitin-like genes are involved in duplication of the microtubule organizing center. 1996, Pubmed
Bloch, Identification and characterization of a leukocyte-specific component of the nuclear body. 1996, Pubmed
Boddy, PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. 1996, Pubmed
Brasch, Nuclear bodies (NBs): a newly "rediscovered" organelle. 1992, Pubmed
Brown, A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. 1997, Pubmed
Carvalho, Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. 1995, Pubmed
Chelbi-Alix, Induction of the PML protein by interferons in normal and APL cells. 1995, Pubmed
Daniel, PML protein expression in hematopoietic and acute promyelocytic leukemia cells. 1993, Pubmed
Dent, LYSP100-associated nuclear domains (LANDs): description of a new class of subnuclear structures and their relationship to PML nuclear bodies. 1996, Pubmed
Desbois, Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I Tax oncoprotein. 1996, Pubmed
de Thé, The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. 1991, Pubmed
de Thé, The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. 1990, Pubmed
Dignam, Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. 1983, Pubmed
Dyck, A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. 1994, Pubmed
Everett, A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. 1997, Pubmed
Gambacorta, Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. 1996, Pubmed
Garrett, Positive regulation of general transcription factor SIII by a tailed ubiquitin homolog. 1995, Pubmed
Goddard, Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. 1991, Pubmed
Grisolano, Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. 1997, Pubmed
Grötzinger, Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). 1996, Pubmed
Grötzinger, A highly amplified mouse gene is homologous to the human interferon-responsive Sp100 gene encoding an autoantigen associated with nuclear dots. 1996, Pubmed
Guldner, IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. 1992, Pubmed
Hochstrasser, Ubiquitin-dependent protein degradation. 1996, Pubmed
Hochstrasser, Protein degradation or regulation: Ub the judge. 1996, Pubmed
Hodgins, The tail of a ubiquitin-conjugating enzyme redirects multi-ubiquitin chain synthesis from the lysine 48-linked configuration to a novel nonlysine-linked form. 1996, Pubmed
Huang, Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. 1988, Pubmed
Kakizuka, Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. 1991, Pubmed
Kamitani, Preferential modification of nuclear proteins by a novel ubiquitin-like molecule. 1997, Pubmed
Kitamura, Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. 1989, Pubmed
Koken, The PML growth-suppressor has an altered expression in human oncogenesis. 1995, Pubmed
Koken, The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. 1994, Pubmed
Korioth, The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1. 1996, Pubmed
Kovalenko, Mammalian ubiquitin-conjugating enzyme Ubc9 interacts with Rad51 recombination protein and localizes in synaptonemal complexes. 1996, Pubmed
Lavau, The acute promyelocytic leukaemia-associated PML gene is induced by interferon. 1995, Pubmed
Le, Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML. 1996, Pubmed
Loeb, The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. 1992, Pubmed
Mahajan, A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. 1997, Pubmed
Matunis, A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. 1996, Pubmed , Xenbase
Maul, Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). 1993, Pubmed
Maul, Nuclear domain 10 (ND10) associated proteins are also present in nuclear bodies and redistribute to hundreds of nuclear sites after stress. 1995, Pubmed
Mu, PML, a growth suppressor disrupted in acute promyelocytic leukemia. 1994, Pubmed
Nakamura, Molecular cloning and characterization of a cDNA encoding monoclonal nonspecific suppressor factor. 1995, Pubmed
Okura, Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. 1996, Pubmed
Powell, Antinuclear antibodies in primary biliary cirrhosis. 1984, Pubmed
Raska, Structure-function subcompartments of the mammalian cell nucleus as revealed by the electron microscopic affinity cytochemistry. 1992, Pubmed
Scully, Association of BRCA1 with Rad51 in mitotic and meiotic cells. 1997, Pubmed
Shen, UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins. 1996, Pubmed
Shen, Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system. 1996, Pubmed
Sternsdorf, Nuclear dots: actors on many stages. 1997, Pubmed
Sternsdorf, Cellular localization, expression, and structure of the nuclear dot protein 52. 1997, Pubmed
Sternsdorf, Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. 1995, Pubmed
Stuurman, A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. 1992, Pubmed
Szostecki, Autoantibodies against "nuclear dots" in primary biliary cirrhosis. 1997, Pubmed
Szostecki, Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100). 1987, Pubmed
Szostecki, Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. 1990, Pubmed
Van de Water, Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. 1988, Pubmed
Watkins, The Saccharomyces cerevisiae DNA repair gene RAD23 encodes a nuclear protein containing a ubiquitin-like domain required for biological function. 1993, Pubmed
Weichenhan, Structure and expression of the murine Sp100 nuclear dot gene. 1997, Pubmed
Weis, Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. 1994, Pubmed
Xie, Nuclear dot antigens may specify transcriptional domains in the nucleus. 1993, Pubmed
Yasugi, Identification of the structural and functional human homolog of the yeast ubiquitin conjugating enzyme UBC9. 1996, Pubmed